Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Future opportunities for passive immunity against viral diseases.

Graham BS.

J Infect Dis. 2011 Dec 1;204(11):1648-50. doi: 10.1093/infdis/jir628. Epub 2011 Oct 12. No abstract available.

2.

Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion.

Schepens B, Ibañez LI, De Baets S, Hultberg A, Bogaert P, De Bleser P, Vervalle F, Verrips T, Melero J, Vandevelde W, Vanlandschoot P, Saelens X.

J Infect Dis. 2011 Dec 1;204(11):1692-701. doi: 10.1093/infdis/jir622. Epub 2011 Oct 12.

3.

Anti-respiratory syncytial virus monoclonal antibodies show promise in the treatment and prophylaxis of viral disease.

Taylor G, Porter T, Dillon S, Trill J, Ganguly S, Hart T, Davis C, Wyde P, Tempest P, Harris W.

Biochem Soc Trans. 1995 Nov;23(4):1063-7. Review. No abstract available.

PMID:
8654682
4.

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion.

Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H.

J Virol. 2010 Aug;84(16):8132-40. doi: 10.1128/JVI.02699-09. Epub 2010 Jun 2.

5.

Monoclonal antibodies against respiratory syncytial virus.

Givner LB.

Pediatr Infect Dis J. 1999 Jun;18(6):541-2. No abstract available.

PMID:
10391187
7.

Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.

Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB.

Pediatr Res. 1995 Oct;38(4):543-50.

PMID:
8559607
9.

Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.

Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ.

Pediatr Infect Dis J. 1999 Mar;18(3):223-31. Review. No abstract available.

PMID:
10093942
10.

[Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections].

[No authors listed]

Z Geburtshilfe Neonatol. 1999 Dec;203 Suppl 2:16. German. No abstract available.

PMID:
10612193
11.

Palivizumab in the prophylaxis of respiratory syncytial virus infection.

Cardenas S, Auais A, Piedimonte G.

Expert Rev Anti Infect Ther. 2005 Oct;3(5):719-26. Review.

PMID:
16207163
12.

Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.

Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA.

Pediatr Infect Dis J. 2009 Sep;28(9):835-7. doi: 10.1097/INF.0b013e3181a165e4.

PMID:
19636278
13.
14.

New vaccines.

Heins JR.

S D J Med. 1999 Jan;52(1):21-2. No abstract available.

PMID:
9926728
15.

Passive antibody prophylaxis for RSV.

DeVincenzo J.

Pediatr Infect Dis J. 2008 Jan;27(1):69-70. Review. No abstract available.

PMID:
18162943
16.

[RSV-prophylaxis--to whom?].

Lossius K.

Tidsskr Nor Laegeforen. 2000 Sep 10;120(21):2494. Norwegian. No abstract available.

17.

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.

Stegmann T, Kamphuis T, Meijerhof T, Goud E, de Haan A, Wilschut J.

Vaccine. 2010 Aug 2;28(34):5543-50. doi: 10.1016/j.vaccine.2010.06.041. Epub 2010 Jun 25.

PMID:
20600502
19.

Antibodies for prevention and treatment of respiratory syncytial virus infections in children.

Geevarghese B, Simões EA.

Antivir Ther. 2012;17(1 Pt B):201-11. doi: 10.3851/IMP2061. Epub 2012 Feb 3. Review.

PMID:
22311607
20.

Recombinant Sendai virus induces T cell immunity against respiratory syncytial virus that is protective in the absence of antibodies.

Voges B, Vallbracht S, Zimmer G, Bossow S, Neubert WJ, Richter K, Hobeika E, Herrler G, Ehl S.

Cell Immunol. 2007 Jun;247(2):85-94. Epub 2007 Sep 29.

PMID:
17904538
Items per page

Supplemental Content

Write to the Help Desk